Company Filing History:
Years Active: 2016
Title: Yumei Tan: Innovator in Hepatitis C Virus Inhibition
Introduction
Yumei Tan is a prominent inventor based in Dongguan, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds aimed at treating hepatitis C virus (HCV) infections. With a total of 2 patents, his work is recognized for its potential impact on public health.
Latest Patents
Yumei Tan's latest patents include innovative compounds that serve as inhibitors of the hepatitis C virus. One of his notable patents is titled "Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof." This patent describes a compound that can be utilized for treating HCV infections or related disorders. The patent outlines various forms of the compound, including stereoisomers and pharmaceutically acceptable salts, which can be incorporated into pharmaceutical compositions for effective treatment.
Another significant patent is "Spiro compounds as Hepatitis C virus inhibitors." This patent discloses spiro compounds that can also be used to treat HCV infections or hepatitis C disease. Similar to his previous work, this patent details the various forms of the compounds and their applications in pharmaceutical compositions aimed at combating HCV.
Career Highlights
Yumei Tan is currently associated with Sunshine Lake Pharma Co., Ltd., where he continues to innovate in the field of antiviral therapies. His research focuses on developing effective treatments for HCV, contributing to the ongoing battle against viral infections.
Collaborations
Yumei Tan collaborates with esteemed colleagues, including Yingjun Zhang and Jiancun Zhang. These partnerships enhance the research and development efforts within the pharmaceutical domain, fostering innovation and progress in HCV treatment.
Conclusion
Yumei Tan's contributions to the field of hepatitis C virus inhibition through his innovative patents highlight his role as a key inventor in pharmaceutical sciences. His work not only advances medical research but also holds promise for improving treatment options for patients affected by HCV.